Full Text View
Tabular View
No Study Results Posted
Related Studies
Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
This study is currently recruiting participants.
Study NCT00202930   Information provided by Tersak, Jean M., M.D.
First Received: September 12, 2005   Last Updated: September 19, 2006   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Neuroblastoma
Opsoclonus-Myoclonus
Additional conditions recognized in this trial
Myoclonus
Ocular Motility Disorders
Opsoclonus-Myoclonus Syndrome
More general conditions related to this trial
Central Nervous System Diseases
Cranial Nerve Diseases
Dyskinesias
Eye Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Nervous System Diseases
Nervous System Neoplasms
Neurodegenerative Diseases
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Neuroectodermal Tumors, Primitive, Peripheral
Neurologic Manifestations
Paraneoplastic Syndromes
Paraneoplastic Syndromes, Nervous System
Signs and Symptoms
Interventions listed in this trial
anti-CD20 (Rituximab)
Additional drug interventions recognized in this trial
Rituximab
More general drug interventions related to this trial
Antineoplastic Agents
Antirheumatic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Tersak, Jean M., M.D.
Genentech


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services